Breaking News
Mike Nolan
About Mike Nolan
Mike brings nearly three decades of experience to his role as Freenome’s Chief Executive Officer, building on a proven record of delivering transformative diagnostic technologies that help clinicians drive better outcomes for their patients. Previously, Mike served as the company’s Chief Business Officer, where he led Freenome’s corporate and business development, product management, clinical development and operations, program management, and marketing teams. He also oversaw partnerships with biopharma companies, academic medical centers, and health systems where our multiomics platform is deployed to move research and medicine forward.
Mike came to Freenome from Foundation Medicine, where he served as SVP of Commercial Operations and led a cross-functional team to expand the use of next-generation sequencing technologies in cancer.
Prior, Mike held global general management and commercial leadership roles for many industry leaders, including Thermo Fisher, Luminex, Roche Molecular Systems, Roche Diagnostics, and Abbott Diagnostics.
Mike holds a B.S. in Biological Sciences and Secondary Education, along with an MBA from the University of Wyoming.
Largest Clinical Study Validating A Blood-based Colorectal Screening Test Completes Enrollment
May 11 2022
Freenome, a privately held biotech company, announced the completion of enrollment for PREEMPT CRC, the […]
Lance Baldo Joins Freenome as Chief Medical Officer
April 5 2022
Freenome, a privately held biotech company, announced today that Lance Baldo, M.D. has joined the […]
Freenome Launches The Vallania Study For The Early Detection Of Multiple Cancers
March 1 2022
Freenome, a privately held biotech company, today announced the initiation of Vallania, a clinical study […]
Freenome Presents Research Highlighting its Multiomics Blood Testing Platform in PREEMPT CRC
January 24 2022
Freenome, a privately held biotech company, presented at the American Society of Clinical Oncology Gastrointestinal […]
Significant Investment Accelerates Freenome's Multiomics Platform for the Early Detection of Cancer
January 12 2022
Freenome, a privately held biotech company, announced today that Roche has made an investment of $290 […]
Freenome Raises $300M in Series D Financing to Advance Multiomics Platform for Early Cancer Detection
December 8 2021
Freenome, a privately held biotech company, today announced a Series D funding of $300 million. […]
Freenome Shows Continued Leadership in Colorectal Cancer Research
October 26 2021
Freenome, a privately held biotech company, presented new research at the American College of Gastroenterology […]
New Study Finds Freenome ’s Multiomics Approach Successful in Detecting Pancreatic Cancer
October 1 2021
Freenome, a privately-held biotech company, presented new research today at the American Association of Cancer […]